Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

GLOW Blend (BPC-157 + TB-500 + GHK-Cu) peptide iconGLOW Blend (BPC-157 + TB-500 + GHK-Cu)25 residues (approx.)GEPPPGKPADDAGLVLKKTETQGHKEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.

GLOW Blend (BPC-157 + TB-500 + GHK-Cu)

Varies by component half-life·Injection·6w on / 2w off

Also known as: GLOW Peptide, GLOW Stack, Triple Healing Stack

Three peptides, three repair pathways, one syringe. The GLOW Blend pairs BPC-157 and TB-500 (the original Wolverine Stack) with GHK-Cu, a copper-binding tripeptide that raises or lowers the activity of at least 4,000 human genes, including ones tied to tissue regeneration (Pickart)[1]. Community users report smoother skin texture and faster injury recovery within three to six weeks. Zero combination trials exist in humans, and all clinical evidence comes from preclinical animal models or tiny pilot studies. Athletes recovering from soft tissue injuries and people chasing collagen density are the primary audience for this stack.

What Is GLOW Blend (BPC-157 + TB-500 + GHK-Cu)?

At least 4,000 human genes respond to a single copper-binding tripeptide. That tripeptide is GHK-Cu, and the GLOW Blend builds an entire healing protocol around it. Full name: BPC-157 + TB-500 + GHK-Cu (also called the triple healing stack). No CAS number exists for the combination.

BPC-157 upregulates VEGF to build new blood vessels at injury sites. It modulates nitric oxide for vascular protection and activates the FAK-paxillin pathway for tendon and ligament repair. TB-500 (the active fragment of Thymosin Beta-4) upregulates actin, a cell-building protein that moves repair cells to wound sites. Thymosin beta-4 also has anti-inflammatory activity, per a 2016 review [5]. GHK-Cu delivers copper ions to tissue, triggering collagen I and III synthesis and decorin expression for organized (not fibrotic) tissue remodeling.

Community adoption sits at roughly 200+ Reddit threads and a 4.3/5 sentiment score. Users consistently describe higher-quality healed tissue compared to BPC-157 plus TB-500 alone, with less scar formation and visible skin improvements by week four. The primary complaint: budget pre-mixed vials deliver roughly 200 mcg of GHK-Cu, which is 5 to 10 times below the community-effective dose of 1 to 2 mg daily.

The honest assessment: zero human combination trials exist. BPC-157 has one published human pilot (n=2, IV only)[2]. TB-500 has no human data at all for the subcutaneous route; the Phase I PK often cited (PMC8419156) studied recombinant full-length thymosin beta-4 given IV. GHK-Cu evidence is primarily in vitro and animal. Promising preclinical data and strong community consensus, but the clinical gap is real.

How GLOW Blend (BPC-157 + TB-500 + GHK-Cu) Works

The GLOW Blend works through three distinct repair pathways that don't overlap.

BPC-157 handles local, targeted repair. It upregulates vascular endothelial growth factor (VEGF) to drive angiogenesis at the injury site. New blood vessel formation accelerates nutrient delivery to damaged tissue. In isolated rat aorta, BPC-157 relaxed the vessel wall in a nitric oxide-dependent way, likely through Src-caveolin-1-eNOS signaling [7]. In rat tendon fibroblasts, it switched on FAK-paxillin signaling and sped cell migration [6]. A follow-up study found it raised growth hormone receptor expression in the same cell type [3].

TB-500 works systemically. As the active fragment of Thymosin Beta-4, it upregulates actin, a protein that enables cell migration and proliferation at wound sites. In Malinda's rat wound study, thymosin beta-4 raised reepithelialization over saline by 42% at day 4 and up to 61% at day 7 [4]. Kleinman and Sosne's 2016 review adds anti-inflammatory activity to its profile [5]. Both results come from full-length thymosin beta-4, not TB-500 itself. The plasma half-life usually cited for it, 0.5 to 2.08 hours, comes from a Phase I study of recombinant full-length thymosin beta-4 given intravenously (PMC8419156). That is a different molecule by a different route. No human dose-finding or PK data exists for subcutaneous TB-500.

GHK-Cu adds the structural remodeling layer. This copper-binding tripeptide delivers copper ions directly to tissue, activating collagen I and III synthesis and promoting decorin expression. Decorin matters because it organizes collagen fibers into functional architecture rather than disorganized scar tissue. Pickart's group counts at least 4,000 human genes that GHK-Cu raises or lowers [1]. A 2015 review from the same group proposed that GHK-Cu acts on antioxidant-related genes, based on the Broad Institute's Connectivity Map gene-expression database (Cosmetics 2015).

The three peptides clear plasma within hours. Structural and gene expression effects persist for weeks after clearance.

GLOW Blend (BPC-157 + TB-500 + GHK-Cu) Benefits

  • GLOW Blend benefits center on multi-pathway tissue repair, collagen remodeling, and systemic inflammation control.
  • Three-pathway healing in a single protocol: BPC-157 for local repair, TB-500 for systemic inflammation, GHK-Cu for structural collagen remodeling. No other peptide stack covers all three simultaneously.
  • Community users report higher-quality healed tissue versus the two-peptide Wolverine Stack, with less fibrotic scar formation (roughly 200+ Reddit threads, 4.3/5 sentiment).
  • GHK-Cu raises or lowers the activity of at least 4,000 human genes, including ones tied to tissue regeneration and antioxidant defense (Pickart)[1]. Skin firmness and elasticity improvements typically appear by week three to four.
  • Thymosin beta-4, TB-500's parent protein, raised reepithelialization in rat wounds 42% over saline at day 4 and up to 61% at day 7 [4]. A 2016 review also credits it with anti-inflammatory activity [5].
  • Single daily injection when using pre-mixed vials simplifies a three-peptide protocol into one subcutaneous dose, though separate vials allow better TB-500 frequency control.
  • Wound healing and skin texture improvements noted within three to six weeks across community reports; fine line reduction and scar softening peak at week six to eight.

GLOW Blend (BPC-157 + TB-500 + GHK-Cu): Science vs Community Consensus

Partially Aligned
Scientific Evidence
Weak
Based on 13 key studies·Research only

No combination studies exist for the three-peptide blend.

Dosing studied: Individual components only: no clinically validated combination dose. BPC-157: 250–500 mcg/day SC; TB-500: 2–5 mg twice weekly SC; GHK-Cu: 1–3 mg/day SC. Market-standard pre-mixed 70mg vial ratio: ~50mg GHK-Cu + 10mg BPC-157 + 10mg TB-500.
Read the evidence (key study, limitations)

Individual components have preclinical (animal) support. BPC-157 has one published human IV safety pilot (n=2, 2025)[2]. TB-500 has no human data for the subcutaneous route; the Phase I PK cited for it (PMC8419156) studied recombinant full-length thymosin beta-4 given IV. GHK-Cu has gene-modulation in vitro data [1]. No RCTs for any component in the healing indications claimed.

Key Study

PMID 40131143 (2025 BPC-157 IV pilot, n=2, no adverse effects on cardiac/hepatic/renal/thyroid biomarkers); PMC12313605 (2025 systematic review BPC-157 orthopaedic sports medicine); PMID 26236730 (GHK-Cu raises or lowers at least 4,000 human genes, 2015 review); PMC8419156 (Phase I human PK of recombinant full-length thymosin beta-4 given IV, plasma t½ 0.5–2.08 hours: a different molecule and route from subcutaneous TB-500, for which no human dose-finding data exists)

Limitations

Zero human combination trials. BPC-157 pilot is n=2, uncontrolled, IV only (not SC). TB-500 human data is PK only: no efficacy endpoints. GHK-Cu data is primarily in vitro and animal. No dose-finding, safety, or efficacy RCTs for any component in humans.

Community Experience
Moderate
4.3/5
Based on ~200+ threads (r/Peptides, r/Nootropics)

Positive sentiment; users report meaningful healing quality improvement vs. BPC-157 + TB-500 alone, attributing collagen and skin/connective tissue benefits to GHK-Cu.

Community dosing: Market-standard 70mg vial (~2.33 mg total/injection in 3mL bac water = ~1.67mg GHK-Cu + 0.33mg TB-500 + 0.33mg BPC-157 daily). Separate-component protocol: BPC-157 500mcg/day + GHK-Cu 2mg/day + TB-500 2mg twice weekly (loading); halved for maintenance.
Read the reports (what users report 5, common issues 5)

Primary concern: GHK-Cu underdosing in budget pre-mixed vials undermines outcomes.

What users report (5)
  • Higher-quality healed tissue vs BPC+TB500 alone: less fibrotic scar formation
  • Skin firmness and elasticity improvements attributed to GHK-Cu collagen synthesis
  • Faster recovery from tendon, ligament, and muscle injuries
  • Systemic inflammation reduction (TB-500 component)
  • Wound healing and skin texture improvements noted within 3–6 weeks
Common issues (5)
  • Budget pre-mixed vials likely deliver ~200mcg GHK-Cu vs effective community dose of 1–2mg (5–10× underdose)
  • Pre-mixed daily vials compromise TB-500 optimal dosing frequency (2×/week vs daily)
  • Copper from GHK-Cu may catalyze oxidation of TB-500 (methionine) and BPC-157 in combined vials
  • Cost significantly higher when GHK-Cu is adequately dosed at 50mg per vial
  • WADA-prohibited: BPC-157 and TB-500 both explicitly banned in competitive sport
Partially Aligned

Individual component science is weak-to-moderate (preclinical dominant; one tiny human pilot for BPC-157). Community use is enthusiastic and broadly positive, but the combination ratios and cycle structures are entirely community-designed. Key divergence: TB-500 community-preferred dosing (2×/week SC) conflicts with daily pre-mixed vial formats sold commercially.

GLOW Blend (BPC-157 + TB-500 + GHK-Cu) Dosage Guide

SpeculativeAnchored on the GHK-Cu component. Community range 1 to 2 mg per day; the originating GLOW protocol states the 5:1:1 ratio and no dose. Totals are ratio arithmetic on that anchor, shown on the page.Source (opens in a new tab)

For the pre-blended 70 mg vial (GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg). Separate vials are covered under the table.

LevelDose / InjectionFrequency
Beginner1.4 mg
DailyTrack
Moderate2.33 mgMatches the dose the originating protocol describes: about 1,670 mcg GHK-Cu per injection.
DailyTrack
Aggressive2.8 mgTop of the 1 to 2 mg per day community range for GHK-Cu. No source establishes a higher blend dose.
DailyTrack
Note:

Your first decision with this stack is vial format. Pre-mixed 70mg vials (typically 50mg GHK-Cu, 10mg BPC-157, 10mg TB-500) simplify everything into one daily draw. Separate component vials cost more time but let you dose TB-500 twice weekly (the community-preferred frequency) and avoid copper-catalyzed oxidation in a shared solution.

Reconstitution math for the 70mg vial with 3 mL bacteriostatic water: concentration is 23.3 mg/mL, so one unit on a U-100 insulin syringe holds about 233 mcg. The beginner tier of 1,400 mcg is 6 units. Moderate (2,330 mcg) is 10 units. Aggressive (2,800 mcg) is 12 units.

Do not carry over syringe unit calculations between vial formats.

The thing most beginners miss: budget pre-mixed vials may contain only 200 mcg of GHK-Cu per dose. That is 5 to 10 times below the effective community dose. A blend's COA should list the exact milligrams of each component.

Component ceilings
  • GHK-Cu: 3,000 mcg per day. Top of the injectable range on the GHK-Cu page (0.5 to 3 mg per day, community). No human dose-finding trial exists for injectable GHK-Cu.

Blend ratios are not standardized. Confirm the milligram breakdown on your COA before dosing. If your ratio differs, the component split above does not apply. Budget vials have been reported at roughly 200 mcg GHK-Cu per dose, 5 to 10 times below the community range.

Which product do you have?

This blend is run in more than one way. The dosing table above describes the pre-blended 70 mg vial only.

Pre-blended 70 mg vialTable above uses thisRatio is market-typical
Inside the one vial
GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg
5:1:1 GHK-Cu : BPC-157 : TB-500

The ratio is fixed at manufacture. You cannot move one component without moving all three. Raising the blend dose raises GHK-Cu with it.

Community cycles run 4 to 8 weeks with a 2-week minimum break. The originating protocol sets no fixed length: it says to run until healing is achieved and take at least 15 days off between cycles. Neither schedule has trial support.

Separate component vialsRatio varies widely
Example vial sizes sold
GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg
Dose each component on its own page
  • GHK-Cu: 2 mg per day loading, halved for maintenance (community). Own page: 1 to 2 mg per day.
  • BPC-157: 500 mcg per day (community). Own page carries the full tier set.
  • TB-500: 2 mg twice weekly (community). The twice-weekly schedule is the reason many users choose separate vials; a pre-blended vial forces daily.

Two sources conflict and neither is authoritative. The originating protocol says to hold the 5:1:1 ratio when dosing separately. Community separate-vial reports use GHK-Cu 2 mg per day, BPC-157 500 mcg per day, and TB-500 2 mg twice weekly, which is not 5:1:1. Both are presented here; pick with a prescriber.

Community cycles run 4 to 8 weeks with a 2-week minimum break.

How the tiers were set

GHK-Cu sets the tier (1 to 2 mg per day, subcutaneous). Community consensus. No human trial establishes an injectable GHK-Cu dose at any level.

GHK-Cu is 50 mg of the 70 mg vial, so it is 71 percent of every draw. The GHK-Cu dose sets the tier and the total follows from the ratio. 1,000 mcg GHK-Cu needs a 1,400 mcg draw. 1,670 mcg needs 2,330 mcg, the amount the originating protocol describes. 2,000 mcg needs 2,800 mcg.

Cycling Protocol

On Period
6 weeks
Off Period
2 weeks

Community cycles run 4 to 8 weeks depending on injury severity, 6 weeks most often, with a 2-week minimum break. The originating GLOW protocol sets no fixed length: it says to run until healing is achieved and take at least 15 days off between cycles. Neither schedule has trial support. For acute injuries 4 to 6 weeks is typical; some users extend to 8 weeks for chronic conditions with provider oversight.

Calculate your GLOW Blend (BPC-157 + TB-500 + GHK-Cu) dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

Print the GLOW Blend protocol card (free PDF)

One page: what is in the vial, the dose each tier delivers per component, syringe units, cycling, and where every number comes from.

GLOW Blend (BPC-157 + TB-500 + GHK-Cu) Protocols by Goal

beginnerCommunity4 to 8 weeks active + 2 weeks off minimum
Start
Wk 1–2
1,400 mcg total blend · Daily · Subcutaneous
Standard
Wk 3–6
2,330 mcg total blend · Daily · Subcutaneous
Off
Wk 7–8
None · None · None

Expected: Community reports describe reduced injury-site inflammation by week 2 and skin texture change by week 3 to 4. No trial measures any endpoint for this combination.

Monitor: Baseline serum copper and ceruloplasmin, repeated mid-cycle. Wilson's disease or copper metabolism disorder: absolute contraindication. WADA athletes: BPC-157 and TB-500 are both prohibited.

How to Use GLOW Blend (BPC-157 + TB-500 + GHK-Cu)

  1. 1
    Step 1

    Gather supplies: reconstituted GLOW vial (or separate component vials), alcohol swabs, 29 or 31 gauge insulin syringe (U-100, 0.5 mL or 1 mL), and a sharps container.

  2. 2
    Clean the vial stopper with an alcohol swab

    Draw the calculated dose. For the pre-blended 70mg vial in 3 mL bac water (23.3 mg/mL): beginner 1,400 mcg = 6 units; moderate 2,330 mcg = 10 units; aggressive 2,800 mcg = 12 units.

  3. 3
    Separate-vial format only

    If you bought three component vials instead of a pre-blended one, draw each peptide into a separate syringe. These numbers do not apply to the pre-blended vial in step 2. BPC-157 and TB-500 assume 10mg vials in 2 mL bac water (5 mg/mL): BPC-157 500 mcg = 10 units, TB-500 2 mg = 40 units (twice weekly only, not daily). GHK-Cu assumes the 50mg vial in 5 mL bac water (10 mg/mL) the GHK-Cu page uses: 2 mg = 20 units.

  4. 4
    Choose your injection site

    For targeted injury repair, inject subcutaneously near the injury. For general healing and systemic recovery, use abdominal subcutaneous injection. Rotate sites every 2 inches from the navel.

  5. 5
    Step 5

    Pinch a fold of skin, insert the needle at a 45-degree angle, inject slowly, and withdraw. Apply light pressure with an alcohol swab.

  6. 6
    Inject in the morning or post-workout for best timing

    If using separate GHK-Cu and BPC-157/TB-500 vials, inject sequentially rather than mixing in one syringe (copper may catalyze degradation).

  7. 7
    Step 7

    Return the reconstituted vial to the refrigerator (2 to 8 degrees Celsius). Use within three to four weeks. Never freeze reconstituted solution.

Alternative Routes

Subcutaneous injection

Reference dose

Abdominal SC preferred; rotate sites every 2 inches from navel. Near-injury injection may enhance local BPC-157 effects for targeted repair.

Intramuscular injection

Same dose; potentially faster peak absorption but increased discomfort

No clinical evidence of meaningful difference vs SC for peptide bioavailability. IM adds injection discomfort without clear benefit for subcutaneous peptides.

Topical (GHK-Cu component only)

Topical GHK-Cu serum (~$30–80/month) can augment injectable protocol for aesthetic goals without replacing injectable dosing

Topical GHK-Cu has documented skin penetration data and is commercially available as a skincare ingredient. BPC-157 and TB-500 topical bioavailability is negligible: these require injection.

Oral (BPC-157 component only)

BPC-157 oral dose typically 1–5 mg (higher than SC 250–500 mcg) to account for GI degradation

For GI-specific BPC-157 applications, oral route is separately used. Not applicable to the full GLOW three-peptide stack: TB-500 and GHK-Cu require injection.

Mixing your own vial? Use the GLOW Blend (BPC-157 + TB-500 + GHK-Cu) reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

GLOW Blend (BPC-157 + TB-500 + GHK-Cu) Stacking Protocols

Works With

Avoid

Copper supplements (oral dietary)

GHK-Cu delivers systemic copper; concurrent copper supplementation risks copper overload, particularly during extended cycles >6 weeks

Anticoagulants (warfarin, heparin, DOACs)

TB-500 may affect clotting pathways; BPC-157 pro-angiogenic effects. Combination with anticoagulants is unstudied; theoretical bleeding risk amplification

Active cancer therapy (esp. anti-angiogenic agents)

BPC-157 promotes angiogenesis via VEGFR2: directly antagonizes anti-angiogenic cancer treatments and theoretically feeds tumor vasculature

Do not combine
Immunosuppressants (cyclosporine, tacrolimus)

TB-500 modulates immune response; interaction with calcineurin inhibitors is unstudied and theoretically unpredictable

Estimated Cost

Generic / Research
70mg pre-mixed GLOW vial (50mg GHK-Cu + 10mg BPC-157 + 10mg TB-500): ~$175–$220/vial research-grade. A 30mg vial format also exists at ~$80–$120, but the component ratio is not stated, so the per-component split on this page does not apply to it. Separate component monthly cost at full loading dose: ~$150–$300.
Compounded
Clinical compounding sessions (physician-supervised): ~$200–$400/treatment. Wolverine Stack (BPC+TB500 only) at clinics: ~$330/package. Full GLOW at IV/peptide clinics: ~$300–$500/month.

Pricing updated 2026-04-09

GLOW Blend (BPC-157 + TB-500 + GHK-Cu) Side Effects

BPC-157 promotes angiogenesis via VEGFR2. That is the most serious safety concern in this stack. Anyone with active cancer or a history of cancer should not use GLOW. New blood vessel formation can theoretically feed tumor vasculature, and this risk is not theoretical enough to dismiss. BPC-157 directly antagonizes anti-angiogenic cancer therapies.

GHK-Cu delivers exogenous copper systemically. Copper excess accumulates in the liver. Early signs include metallic taste, nausea, and abdominal discomfort. Users with Wilson's disease or any copper metabolism disorder have an absolute contraindication to this stack. Serum copper and ceruloplasmin testing at baseline is recommended, with repeat testing at week six for extended cycles or GHK-Cu doses above 2 mg daily. Target ranges: serum copper 70 to 140 mcg/dL, ceruloplasmin 20 to 40 mg/dL.

TB-500 may affect clotting pathways. The interaction with anticoagulants (warfarin, heparin, DOACs) is unstudied in humans; theoretical bleeding risk exists. Unusual bruising or bleeding warrants immediate discontinuation.

Injection site reactions are common across all three components. Redness, mild swelling, and irritation usually resolve within hours. GHK-Cu has a visible blue-teal tint from copper chelation. Mild discoloration at the injection site is normal and clears within 24 hours. Persistent swelling or redness points to insufficient site rotation.

Community-reported side effects during week one include mild headache, occasional nausea, and lightheadedness. GHK-Cu may cause skin flushing on the first injection at higher doses. These typically resolve by week three.

Human safety data is extremely limited. BPC-157 has one published pilot with two participants (IV route only)[2]. TB-500 human data covers pharmacokinetics only. GHK-Cu evidence is primarily in vitro and animal. The total number of humans formally studied on any component in this stack is under 50.

When to stop: persistent headache lasting more than 48 hours; metallic taste or nausea that doesn't resolve; unusual bruising or bleeding; signs of infection at the injection site; any active cancer diagnosis. When to see a doctor: copper excess symptoms, allergic reaction (hives or difficulty breathing), or any effect that feels wrong.

Pregnancy and breastfeeding: do not use. No reproductive safety data exists for any component.

Common Issues & Solutions

No results by week 3: Verify GHK-Cu is adequately dosed. Budget pre-mixed vials may contain ~200 mcg GHK-Cu vs. the effective community dose of 1–2 mg. Check the COA for exact component mg breakdown; switch to separate vials if unverifiable.

Injection site turns bluish: GHK-Cu has a visible blue/teal tint due to copper chelation: mild discoloration at the injection site is normal and resolves within 24 hours. Persistent swelling or redness indicates insufficient site rotation.

Metallic taste or nausea after injection: Early indicator of copper sensitivity or mild copper excess from GHK-Cu. Reduce GHK-Cu dose by 50% for one week; discontinue if symptoms persist >48 hours.

No TB-500 effect: If using a pre-mixed daily vial, TB-500 is delivered in small daily fractions rather than the community-preferred 2×/week dosing. TB-500 tissue effects are dose-pulse–dependent in preclinical models: switch to separate vials for proper twice-weekly schedule.

Your vial ratio does not match 50/10/10: blend ratios are not standardized, and other splits are sold. The total mcg your calculator shows is still correct for any vial size you enter, but the per-component split on this page assumes 5:1:1 and will be wrong for a vial built to a different ratio. Read the COA, then work out the split from the milligram breakdown printed on it.

Ask AI about this page

Ask AI for a second opinion on GLOW Blend (BPC-157 + TB-500 + GHK-Cu) dosing and side effects

Contraindications

  • Active cancer or history of cancer (BPC-157 promotes angiogenesis which may feed tumor growth)
  • Pregnancy or breastfeeding
  • Wilson's disease or copper metabolism disorders (due to GHK-Cu)
  • Active bleeding disorders
  • Known allergy to any component peptide

Drug Interactions

  • Anticoagulants (TB-500 may affect clotting pathways)
  • Copper supplements (risk of copper overload with GHK-Cu)
  • Immunosuppressants (may alter immune modulation effects)
  • NSAIDs (BPC-157 may counteract NSAID-induced GI damage, but interactions are unstudied in humans)
  • Anticoagulants (warfarin, heparin, DOACs)
  • Active cancer therapy (esp. anti-angiogenic agents)

Product Quality

Recommended Monitoring

TestWhenTarget
Serum copper / ceruloplasminBaseline before starting; repeat at week 6 for extended cycles or GHK-Cu doses >2 mg/daySerum copper: 70–140 mcg/dL; ceruloplasmin: 20–40 mg/dL
Liver function panel (ALT, AST, bilirubin)Baseline; repeat if metallic taste, nausea, or other copper excess signs emergeNot listed
CBC with differentialBaseline recommended for extended cycles (>8 weeks)Not listed
Cancer screening (age-appropriate)Before starting, particularly for users >40 or with relevant family historyNot listed
Serum copper / ceruloplasmin

GHK-Cu delivers exogenous copper systemically; monitor for copper accumulation, particularly with high GHK-Cu doses or pre-existing liver conditions

Liver function panel (ALT, AST, bilirubin)

Copper excess can cause hepatic accumulation. Standard safety monitoring for any injectable protocol.

CBC with differential

Copper at elevated levels affects hematopoiesis; BPC-157 modulates platelet function in animal models. Baseline establishes reference range.

Cancer screening (age-appropriate)

BPC-157 promotes angiogenesis via VEGFR2: absolute contraindication if active cancer. Ensure no occult malignancy before starting.

GLOW Blend (BPC-157 + TB-500 + GHK-Cu) Before and After

Week 1-2

Reduced inflammation and pain at injury sites. Initial healing response begins.

Week 3-4

Noticeable improvement in mobility and tissue repair. Collagen remodeling from GHK-Cu becomes apparent.

Week 5-6

Significant recovery milestones. Scar tissue softening. Many users report near-full recovery from moderate injuries. End of standard 6-week cycle: evaluate results.

Week 7-8
off cycle

Two-week break. Healing continues from accumulated effects. Assess whether another cycle is needed or transition to single-peptide maintenance.

What to Expect

Week 1 to 2, Inflammation Reduction: BPC-157 begins modulating nitric oxide signaling and VEGF expression within 24 to 72 hours in animal models. TB-500 reduces pro-inflammatory cytokines acutely. GHK-Cu starts activating antioxidant genes. Community users report improved sleep, reduced pain and swelling at injury sites, and early wound healing acceleration. Some notice gut comfort improvements within the first week. Expect mild injection site redness that resolves within hours, occasional headache during days one through three, and possible nausea if the GHK-Cu dose is high on the first injection.

Week 3 to 4, Tissue Remodeling Begins: VEGF-driven angiogenesis supports new vessel formation. TB-500 actin upregulation drives cell migration, with preclinical wound studies showing 42 to 61% increases in reepithelialization versus controls. GHK-Cu collagen I and III synthesis ramps up. Community reports describe smoother skin texture, increased elasticity, and a visible "glow." Athletes report returning to training with reduced pain. Side effects are usually resolved by this point; occasional persistent injection site marking if rotation is insufficient.

Week 5 to 8, Peak Healing and Collagen Density: GHK-Cu collagen remodeling favors organized architecture over fibrotic scar tissue through decorin expression. BPC-157 FAK-paxillin pathway effects on tendon repair mature at four to six weeks in preclinical models. Community users report scar tissue softening, fine line reduction, near-full recovery from moderate soft tissue injuries, and peak skin elasticity improvements. The "glow" effect is most pronounced during this window. Minimal side effects if cycling properly and copper dose stays reasonable.

Post-Cycle Weeks 9 to 10, Sustained Effects: All three peptides clear plasma within hours, but structural effects driven by downstream gene expression persist. GHK-Cu gene modulation may outlast plasma presence. Community users report maintained elasticity and scar improvements four to eight weeks post-cycle. This is the assessment window: determine whether a second cycle is needed for chronic conditions or whether improvement continues without intervention.

Detailed Timeline: Science vs Community

Week 1–2
Science

BPC-157 modulates nitric oxide signaling and VEGF expression within 24–72 hours (animal models). TB-500 reduces pro-inflammatory cytokines acutely. GHK-Cu begins antioxidant gene activation.

Community

Improved sleep, reduced pain and swelling at injury site, early wound healing acceleration, some report gut comfort improvement within first week.

Week 3–4
Science

VEGF-driven angiogenesis supports new vessel formation; TB-500 actin upregulation drives cell migration and reepithelialization (42–61% increase vs controls in preclinical wound studies). GHK-Cu collagen I/III synthesis upregulation ramps up.

Community

Smoother skin texture, increased elasticity, visible "glow," improved mobility. Athletes report returning to training with reduced pain.

Week 5–8
Science

GHK-Cu collagen remodeling favors organized vs. fibrotic architecture (decorin expression). BPC-157 FAK-paxillin pathway effects on tendon repair mature at 4–6 weeks in preclinical models.

Community

Scar tissue softening, fine line reduction, near-full recovery from moderate soft tissue injuries, peak skin elasticity improvements. Community-reported "glow" effect most pronounced.

Post-Cycle (Weeks 9–10 off)
Science

Collagen remodeling continues after peptide clearance (all three peptides clear plasma within hours; structural effects driven by downstream gene expression persist). GHK-Cu gene modulation effects may outlast plasma presence.

Community

Maintained elasticity and scar improvements reported 4–8 weeks post-cycle. Users assess whether second cycle is needed for chronic conditions vs. continued improvement.

Pharmacokinetics

Half-Life
4h
Bioavailability
SC: varies by component (~65-90%)
Tmax
BPC-157: ~1h; TB-500: ~2-3h; GHK-Cu: ~30min
Data Confidence
low

Source: Estimated from primary component BPC-157 (~4h). The 0.5-2 hour plasma half-life often quoted for TB-500 comes from a Phase I study of recombinant full-length thymosin beta-4 given intravenously (PMC8419156), not the subcutaneous heptapeptide sold as TB-500. No human PK data exists for subcutaneous TB-500. GHK-Cu half-life is ~1 hour. Effective duration is driven by downstream biological activity, not plasma half-life.

Molecular Profile

Amino Acids
25
Sequence
GEPPPGKPADDAGLVLKKTETQGHK
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: N/A (combination product, no single CAS)

Who Should Consider GLOW Blend (BPC-157 + TB-500 + GHK-Cu)

  • Athletes recovering from injuries
  • Post-surgical recovery patients
  • Individuals with chronic tendon or ligament issues
  • Those seeking accelerated wound healing
  • People with joint pain or chronic inflammation

Related Peptides

What Changed for GLOW Blend (BPC-157 + TB-500 + GHK-Cu)

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 202613 Citations

References

  1. [1]GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration (Biomed Res Int 2015) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Safety of intravenous infusion of BPC-157 in humans: a pilot study (Lee et al., Altern Ther Health Med 2025) (opens in a new tab)(n=2,)PubMed (opens in a new tab)PubMed
  3. [3]Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]Thymosin beta4 accelerates wound healing (Malinda et al., J Invest Dermatol 1999) (opens in a new tab)PubMed (opens in a new tab)PubMed
  5. [5]Thymosin beta 4 promotes dermal healing (opens in a new tab)PubMed (opens in a new tab)PubMed
  6. [6]The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration (opens in a new tab)PubMed (opens in a new tab)PubMed
  7. [7]Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway (Hsieh et al., Sci Rep 2020) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Room temperature up to 1 month, refrigerate at 2-8°C for up to 12 months, freeze at −20°C only for storage beyond 12 months
After Reconstitution
Refrigerate at 2-8°C, use within 3-4 weeks
Temperature
2-8°C (36-46°F) after reconstitution

Frequently Asked Questions

The GLOW Blend combines BPC-157, TB-500, and GHK-Cu into a single healing-focused protocol. BPC-157 drives local repair through angiogenesis and growth factor expression. TB-500 promotes systemic cell migration. GHK-Cu raises or lowers the activity of at least 4,000 human genes, including ones related to tissue remodeling and copper-dependent repair enzymes.

It depends on which product you have. A pre-blended 70 mg vial holds about 50 mg GHK-Cu, 10 mg BPC-157, and 10 mg TB-500, a 5:1:1 split fixed at manufacture. GHK-Cu is 71 percent of every draw, so the GHK-Cu dose sets the tier. A 1,400 mcg draw delivers 1,000 mcg GHK-Cu with 200 mcg each of BPC-157 and TB-500. A 2,330 mcg draw delivers about 1,670 / 330 / 330, which is the dose the originating protocol describes. A 2,800 mcg draw delivers 2,000 / 400 / 400. You cannot move one component without moving all three. With separate vials you set each dose yourself. Community reports use GHK-Cu 2 mg per day, BPC-157 500 mcg per day, and TB-500 2 mg twice weekly. The originating protocol instead says to hold the 5:1:1 ratio when dosing separately. Those two do not agree and neither has trial support, so treat the choice as one to make with a prescriber. Blend ratios vary. Check the COA before you calculate anything.

Each component has minimal individual side effect profiles in community reports. The most common complaints are temporary brain fog, mild lethargy in the first week, and injection site soreness when combining multiple peptides. GHK-Cu can cause metallic taste at higher doses. Running three peptides simultaneously increases injection volume and frequency.

Community reports describe noticeable skin improvements from GHK-Cu within 2-3 weeks and soft tissue healing benefits from BPC-157 and TB-500 within 2-4 weeks. Community cycles run 4 to 8 weeks, 6 weeks most often. Hair and nail improvements from GHK-Cu typically require 4-8 weeks.

GLOW Blend (BPC-157 + TB-500 + GHK-Cu) typically comes in 70mg vials. Add 3mL of bacteriostatic water to the vial. Use the free calculator for exact syringe units based on your desired dose. These totals apply to the pre-blended 70 mg vial, 5:1:1 GHK-Cu : BPC-157 : TB-500. Doses for separate component vials are set per component and are not the totals above. Ratios vary between products, so check the COA.